UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004642
Receipt number R000005537
Scientific Title Comparison of glycemic control among diabetics using the defferent insulin pen needles.
Date of disclosure of the study information 2010/12/01
Last modified on 2012/07/03 19:52:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of glycemic control among diabetics using the defferent insulin pen needles.

Acronym

Comparison of glycemic control

Scientific Title

Comparison of glycemic control among diabetics using the defferent insulin pen needles.

Scientific Title:Acronym

Comparison of glycemic control

Region

Japan


Condition

Condition

Type 1 and 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluate efficacy and safety of BD Microfine plus 32G x 4mm Pen Needle by examining whether it provides equivalent glycemic control in diabetic subjects as Novo Pen needle 32G x 6mm by measuring glycated albumin values. Survey patient comfort on this new needle as well.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Average variation rates between glycated albumin level after one-month use of BD Microfine plus 32G x 4mm and that after one-month use of Novo Pen needle 32G x 6mm.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Pseudo-randomization


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Use BD Microfine plus 32G x 4mm for insulin injection during the first 4 weeks and use Novo Pen needle 32G x 6mm during next 4 weeks.

Interventions/Control_2

Use Novo Pen needle 32G x 6mm for insulin injection during the first 4 weeks and use BD Microfine plus 32G x 4mm during next 4 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Type 1 and 2 diabetic patients at the age of 20 years or older
2)Insulin-requiring diabetics who have used a pen device for at least one year prior to Study Visit 0
3)Patients who need two or more injections per day.
4)Patients who measure blood glucose level themselves at home.
5)Patients who have maintained a stable Hemoglobin A1C level from 5.5% to 8.5%.
6)Body Mass Index is under 35.
7)Patients who have a will to complete all the procedures of this investigation.
8)Patients who can fill in results on the CRFs.
9)Patients who can understand informed consent and have a will to enroll in this investigation.

Key exclusion criteria

1)Pregnancy or possibility of pregnancy.
2)Lactating women
3)Serious neurological diseases
4)Physical conditions which unable subjects to carry out the study procedures (e.g., Incapability to inject by themselves).
5)Thyroid deficiencies and/or nephrotic syndrome.
6)Patients who are currently enrolled in another clinical study
7)Patients who have already discussed details with employees of BD Japan or enrolled study subjects regarding the Investigation.
8)Patients for whom Principle Investigator or Investigators consider that their enrollment could expose them to any risk.
9)Patients who can confuse the interpretation of investigation results or who have done.
10)Employees of pharmaceutical or medical device companies.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masato Odawara

Organization

Tokyo Medical University

Division name

The 3rd Department of Internal Medicine

Zip code


Address

160-0023 6-7-1, Shinjuku-ku, Nishi-shinjuku, Tokyo

TEL

03-3342-6111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Takashi Miwa

Organization

Tokyo Medical University

Division name

The 3rd Department of Internal Medicine

Zip code


Address

160-0023 6-7-1, Shinjuku-ku, Nishi-shinjuku, Tokyo

TEL

03-3342-6111

Homepage URL


Email

miwa-t@tokyo-med.ac.jp


Sponsor or person

Institute

Tokyo Medical University
The 3rd Department of Internal Medicine

Institute

Department

Personal name



Funding Source

Organization

Nippon Becton Dickinson Company, Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京医科大学病院(東京都)/Tokyo Medical University Hospital (Tokyo)


Other administrative information

Date of disclosure of the study information

2010 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 03 Month 25 Day

Date of IRB


Anticipated trial start date

2010 Year 10 Month 01 Day

Last follow-up date

2011 Year 03 Month 01 Day

Date of closure to data entry

2011 Year 04 Month 01 Day

Date trial data considered complete

2011 Year 04 Month 01 Day

Date analysis concluded

2011 Year 04 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 12 Month 01 Day

Last modified on

2012 Year 07 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005537


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name